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• In all, 1794 (83%) patients were Caucasian 
and 369 (17%) were Japanese. All the main 
clinical and pathological features were 
significantly different between the two 
ethnicities.
• The median follow-up of the whole cohort 
was 36 months. At last follow-up, 554 
patients (26%) developed disease 
recurrence and 461 (21%) were dead 
from UTUC.
• The 5-year RFS and CSS estimates 
were 71.5% and 74.2%, respectively, for 
Caucasian patients compared with 68.8% 
and 75.4%, respectively, for Japanese 
patients.
• On univariable Cox regression analyses, 
ethnicity was not significantly associated 


















Study Type – Therapy (case series)




• To assess the impact of differences 
in ethnicity on clinico-pathological 
characteristics and outcomes of patients 
with upper urinary tract urothelial 
carcinoma (UTUC) in a large multi-center 





• We retrospectively collected the data of 
2163 patients treated with RNU at 20 
academic centres in America, Asia, and 
Europe.
• Univariable and multivariable Cox 
regression models addressed recurrence-free 
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What’s known on the subject? and What does the study add?
 
The differential effect of ethnicity on clinico-pathological features and cancer-related 
outcomes remains uninvestigated in upper tract urothelial carcinoma.
Ethnicity was not an independent predictor of either recurrence or cancer-related death 
in upper tract urothelial carcinoma.
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The incidence of cancer and its biological 
behaviour varies considerably among 
ethnicities and between geographic areas 
[1–3]. For example, epidemiological studies 
originating from the USA show that tumour 
stage and mortality rates for many cancers 
including those arising from breast, colon and 
rectum, kidney, prostate, and lung are highest 
in African-Americans followed by Whites and 
are lowest in Asians/Pacific Islanders [4–6]. 
Similarly, for bladder urothelial carcinoma 
(UC), African-Americans have worse overall 
survival when compared with Caucasian 
patients [7–10]. Although much of this 
difference has been attributed to higher stage 
at presentation in African-Americans [8,9], 
outcome disparities still persist after 
controlling for tumour stage, grade, 
treatment effect, and other cause mortality 
[10]. Potential differences contributing to 
these disparities among ethnicities and 
geographic locations include delays in 
presentation/diagnosis, inherent biological 
behaviour of the tumour, socioeconomic 
status, lack of adequate health care access, 
differences in exposure to environmental risk 
factors such as smoking, and social support. 
For upper urinary tract UC (UTUC), to our 
knowledge, the differential effect of 
ethnicity on clinico-pathological features and 
cancer-related outcomes remains 
uninvestigated.
Therefore, the purpose of the present study 
was to assess the effect of differences 
in ethnicity on clinico-pathological 
characteristics and outcomes of patients with 
UTUC in a large multi-center series of patients 
treated with radical nephroureterectomy 
(RNU) in three continents (America, Asia, and 
Europe), encompassing nine countries (USA, 
Canada, Japan, Austria, France, England, 




This was an Institutional Review Board-
approved study with all participating sites 
providing the necessary institutional data 
sharing agreements before initiation of the 
study. In all, 20 academic centres worldwide 
provided data. A computerized databank was 
generated for data transfer. After combining 
the datasets, reports were generated for each 
variable to identify data inconsistencies and 
other data integrity problems. Through 
regular communication with all sites, 
resolution of all identified anomalies was 
achieved before analysis. Before final analysis, 
the database was frozen, and the final data 
set was produced for the present analysis.
The database comprised 2217 patients who 
underwent RNU with ipsilateral bladder cuff 
resection between 1987 and 2008. After 
exclusion of patients in whom ethnicity was 
unknown (six patients), and of the few 
patients that were African-American (27) or 
Hispanic (21), the 2163 patients left were the 
subjects of the present analysis.
Surgery was performed by several surgeons 
according to the standard criteria for RNU, i.e. 
extrafascial dissection of the kidney with the 
entire length of ureter and adjacent segment 
of the bladder cuff. The hilar and regional LNs 
adjacent to the ipsilateral great vessel 
generally were resected together with 
enlarged LNs if abnormal on preoperative CT 
or palpable intraoperatively. Extended 
lymphadenectomy was not routinely 
performed.
All surgical specimens were processed 
according to standard pathological 
procedures at each institution. Tumours were 
staged according to the American Joint 
Committee on Cancer–Union Internationale 
Contre le Cancer TNM classification. [11]. 
Tumour grading was assessed according to 
the to the 1998 WHO/International Society of 
Urologic Pathology consensus classification 
[12].
Patients were generally followed-up every 3–
4 months for the first year after RNU, every 6 
months from the second through to the fifth 
year, and annually thereafter. Follow-up 
consisted of a history, physical examination, 
routine blood work and serum chemistry 
studies, urinary cytology, chest radiography, 
cystoscopic evaluation of the urinary bladder, 
and radiographic evaluation of the 
contralateral upper urinary tract. Elective 
bone scan, chest CT, and MRI were performed 
when clinically indicated.
Disease recurrence was defined as local 
failure in the operative site, regional LNs, or 
distant metastasis. Bladder recurrences were 
not considered in the analysis of the 
recurrence-free survival (RFS) rate. Cause of 
death was determined by the treating 
physicians, by chart review corroborated by 
death certificates, or by death certificates 
alone. Most patients who were identified as 
having died from UTUC had progressive, 
widely disseminated metastases at the time of 
death. Patients who died in the perioperative 
period (i.e. death within 30 days of surgery) 
were censored at time of death for cancer-
specific survival (CSS) analyses.
The Fisher’s exact test and the chi-square test 
were used to evaluate the association 
between categorical variables. Differences in 
variables with a continuous distribution 
across dichotomous categories were assessed 





Meier method was used to calculate survival 
functions, and differences were assessed with 
the log-rank statistic. Univariable and 
multivariable Cox regression models 
addressed time to recurrence and cancer-
specific mortality after RNU. Statistical 
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• There were major differences in the 
clinico-pathological characteristics of 
Caucasian and Japanese patients.
• However, RFS and CSS probabilities 
were not affected by ethnicity and race 
was not an independent predictor of 
• On multivariable Cox regression analyses 
that adjusted for the effects of age, gender, 
surgical type, T stage, grade, tumour 





, lymphovascular invasion, 
tumour necrosis, and lymph node status, 
ethnicity was not associated with either RFS 
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ASSOCIATION OF ETHNICITY WITH CLINICAL 
AND PATHOLOGICAL FEATURES
In all, 1794 (83%) patients were Caucasian 
and 369 (17%) were Japanese. Table 1 shows 
the association of clinical and pathological 
features with ethnicity. Patients’ age, gender, 
tumour stage, tumour grade, prevalence 
of lymphovascular invasion, tumour 
architecture, prevalence of tumour necrosis, 





(CIS), and use of adjuvant chemotherapy were 









 0.05). Moreover, also 
follow-up duration from RNU was slightly 









ASSOCIATION OF RACE WITH 
CLINICAL OUTCOMES
The median (interquartile range, IQR) follow-
up of the whole cohort was 36 (15.3–71.1) 
months. At last follow-up, 554 patients (26%) 
had developed disease recurrence and 461 
(21%) were dead from UTUC. Moreover, 301 
patients (14%) had noncancer-related deaths. 
The median (IQR) follow-up for patients alive 
at last follow-up was 45 (20–81) months. The 
overall 5- and 10-year RFS estimates were 









1.3%) respectively. The overall 5- and 10-year 



















 1.2%), respectively, 















 value 0.23 for RFS and 0.75 for 
CSS).
Tables 2 and 3 summarize univariable and 
multivariable analyses for prediction of RFS 
and CSS, respectively. On univariable Cox 
regression analyses, ethnicity was not 

















 0.752). On multivariable 
Cox regression analyses that adjusted for the 
effects of age, gender, surgical type, T stage, 
grade, tumour architecture, presence of 
concomitant CIS, lymphovascular invasion, 
tumour necrosis, and lymph node (LN) status, 
ethnicity was not associated with either RFS 


















Re-analysis of the data after exclusion 
of 224 patients who received adjuvant 
chemotherapy yielded consistent statistical 





















 0.730 for 
CSS). Further subgroup analyses in patients 
with pathologically localized, locally-
advanced, N0/Nx, or N positive disease yielded 





In the present multi-institutional study 




Association of race with clinical and pathological characteristics of 2163 patients treated with 








Number of patients (%) 2163 (100) 1794 (83) 369 (17)














– Male 1478 (68) 1186 (66) 292 (79)
– Female 685 (32) 608 (34) 77 (21)





– Open 1790 (83) 1486 (83) 304 (82)






– Performed 604 (28) 490 (27) 114 (31)






– pT0 10 (0.5) 10 (0.5) 0
– pTa 450 (21) 382 (21) 68 (18)
– pTis 36 (2) 26 (1.5) 10 (3)
– pT1 488 (23) 426 (24) 62 (17)
– pT2 401 (18.5) 330 (18) 71 (19)
– pT3 667 (31) 535 (30) 132 (36)










– Low 655 (30) 587 (33) 68 (18)






– Absent 1682 (78) 1372 (77) 310 (84)










– Papillary 1660 (77) 1351 (75) 309 (84)










– Absent 1667 (77) 1354 (76) 313 (85)






– Absent 1671 (77) 1368 (76) 303 (82)
– Present 492 (23) 426 (24) 66 (18)






– N0 419 (19) 336 (19) 83 (23)















– no 1928 (89) 1629 (91) 299 (81)
– yes 224 (10) 154 (9) 70 (19)
Median (IQR) follow-up, months 36 (15.3–71.1) 35.1 (15.5–69) 38 (15–84) 0.039
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undergoing RNU there were major differences 
in the clinico-pathological characteristics of 
Caucasian and Japanese patients. However, 
RFS and CSS probabilities were not affected 
by ethnicity and race was not an independent 
predictor of either recurrence or cancer-
related death, once adjusted for the effects of 
other clinical and pathological covariates.
It is well established by epidemiological 
studies that rates of cancers incidence and 
deaths vary considerably among racial 
groups. Data from the National Center for 
Health Statistics concerning statistics 
collected from 1930 to 2006 in the USA 
showed that African-Americans had 
incidence and death rates that were 
consistently higher than in Whites for all 
cancer sties, excluding breast, lung and kidney 
cancers [4,5]. Specifically, all site incidence 
and mortality rates were 651.5 and 313 per 
100 000 in male African-Americans and 389 
and 186.7 per 100 000 in female African-
Americans, respectively, compared with 551.4 
and 230.7 per 100 000 in male White and with 
423.6 and 159.2 per 100 000 in female White, 
respectively. Significantly lower figures, 
indeed, were shown for Asian-American and 
Hispanic, compared with both African-
American and White [4].
However, specific epidemiological data for 
UTUC are missing, due to the low prevalence 
of the disease and, above all, to the lack of a 
specific code able to distinguish RCC and 
renal pelvis UTUC in the International 
Classification of Diseases. However, figures for 
bladder UC reconfirmed a similar trend, with 
significantly higher incidence and mortality 
rates in White patients (22.8 and 4.5 per 
100 000, respectively), compared with 
African-American (12.8 and 3.7 per 100 000, 
respectively), Asian-American (9.3 and 1.7 per 
100 000, respectively), and Hispanic patients 
(11.4 and 2.4 per 100 000, respectively) [6]. In 
the present analysis, there was a high 
prevalence of non-organ confined (43%) and 
high-grade (82%) disease in Asiatic patients, 
which is in agreement with previous report 
from Taiwan [13,14], where pT3–4 disease 
might be as frequent as 50%. Several 
hypotheses can be made to explain the 
differences in the clinical and pathological 
characteristics of UTUC at presentation. For 
example, environmental and occupational 
exposures, lifestyle choices such as smoking 
and nutrition, and socioeconomic and cultural 
factors involving access to and the 
willingness to seek care may account for such 
differences [15]. However, despite the large 
number of patients, we were unable to find 
any statistically significant differences in RFS 
and CSS probabilities, between these two 
racial groups. Moreover, the few African-
American and Hispanic patients in our dataset 
prevented us from including them in the 
analysis.
For the other predictors of RFS and CSS, in our 
multivariable models we showed that 
patients’ age at surgery, pathological stage of 
the primary tumour, tumour grade, presence 
of lymphovascular invasion, tumour 
architecture, and LN stage were independent 
predictors of both recurrence and survival, 
while type of surgery was significantly 
associated only with cancer-related death. 
The data of the present study reproduced and 
validated those previously available on pT 
stage and grade [16,17], lymphovascular 
invasion [18,19], architecture [20], and LN 
stage [21]. Notably, patients undergoing 
laparoscopic RNU had worse CSS once 
adjusted for the effects of the other 




Kaplan–Meier curves of RFS and
CSS stratified by patients’ race in
2163 patients treated with RNU
and ipsilateral bladder-cuff
excision for UTUC. Green,
Caucasian patients; blue,
Japanese patients. Log-rank P
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Simone et al. [22], who showed that 
laparoscopic surgery may jeopardize the 
outcome of patients with locally advanced 
disease. However, similar data were not 
reproduced in large multi-institutional 
comparative studies [23,24].
There are several limitations to the present 
study. First and foremost are the limitations 
inherent to retrospective analyses. Although 
we have done multiple internal and external 
reviews of our consortium dataset, we 
excluded from this analysis patients for whom 
we could not obtain complete information, 
which could possibly create selection bias. In 
addition, the population in this study 
underwent RNU by multiple surgeons, 
indication and extension of LN dissection 
were not standardized, and the follow-up 
lacked uniformity. However, all surgeons 
operated at selected centres with significant 
experience in UC management, which might 
increase the external validity of the data, 
compared with the single-centre, single-
surgeon setting. Similarly, whereas it may be 
preferable for a single pathologist specialized 
in genitourinary pathology to review each 
specimen, the multi-centric nature of the 
present study and the use of institutional 
pathological interpretation possibly make the 
results more relevant in the daily clinical 
setting. Nevertheless, all specimens were 
examined by dedicated genitourinary 
pathologists at selected centres. Another 
limitation is that there were few Hispanic and 
African-American patients, which prevented 
us from drawing conclusions on these racial 
groups. In addition we did not control 
for important factors such as patient 
comorbidity, socioeconomic status, marital 
status and other measures of social support, 
body mass index, and smoking status, which 
have been shown to be of interest in some 
reports [25–27].
In conclusion, there were major differences in 
the clinico-pathological characteristics of 
Caucasian and Japanese patients. However, 
RFS and CSS probabilities were not affected 
by ethnicity and race was not an independent 
predictor of either recurrence or cancer-
related death, once adjusted for the effects of 
other clinical and pathological covariates. In 
terms of racial differences of biological 
behaviour, future research is warranted to 
take into account the components, including 
environmental and occupational exposures, 
lifestyle choices, socioeconomic, cultural and 
genetic factors.
TABLE 2 Univariable and multivariable Cox regression analyses of race for prediction of disease 
recurrence in 2163 patients treated with RNU and ipsilateral bladder-cuff excision for UTUC (554 
recurrences)
Variable
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Age 1.01 (1–1.02) 0.001 1.01 (1.01–1.02) 0.017
Race 1.1 (0.9–1.4) 0.231 1.1 (0.9–1.4) 0.447
Gender 1.1 (0.9–1.4) 0.139 1.1 (0.9–1.3) 0.558
Type of RNU (open vs lap.) 0.8 (0.6–1.0) 0.048 0.9 (0.7–1.2) 0.437
Pathological stage: <0.001 <0.001
– pTa/Tis 1, Reference – 1, Reference –
– pT1 1.6 (1.01–2.5) 0.043 1.3 (0.8–2.0) 0.309
– pT2 4.2 (2.9–6.3) <0.001 3.0 (1.9–4.4) <0.001
– pT3 9.2 (6.4–13.2) <0.001 5.1 (3.4–7.7) <0.001
– pT4 37.6 (24.9–56.7) <0.001 14.7 (9.2–23.5) <0.001
Grade 4.1 (3.2–5.3) <0.001 1.8 (1.4–2.4) <0.001
Lymphovascular invasion 3.6 (3.0–4.2) <0.001 1.4 (1.2–1.8) <0.001
Tumour architecture 3.8 (3.2–4.5) <0.001 1.4 (1.1–1.7) 0.003
Tumour necrosis 2.2 (1.9–2.6) <0.001 0.9 (0.7–1.1) 0.205
Concomitant CIS 1.6 (1.4–2.0) <0.001 1.1 (0.9–1.4) 0.178
LN stage: <0.001 <0.001
– N0 1, Reference – 1, Reference –
– Nx 0.9 (0.8–1.2) 0.954 1.3 (0.9–1.6) 0.054
– N+ 4.6 (3.5–6.0) <0.001 2.1 (1.6–2.8 <0.001
Lap., laparoscopic.
TABLE 3 Univariable and multivariable Cox regression analyses of patients’ race for prediction of cancer-
specific mortality in 2163 patients treated with RNU and ipsilateral bladder-cuff excision for UTUC (461 
cancer-specific deaths)
Variable
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Age 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) <0.001
Race 1.1 (0.8–1.3) 0.752 1.01 (0.8–1.3) 0.908
Gender 1.1 (0.9–1.3) 0.542 0.9 (0.7–1.1) 0.407
Type of RNU (open vs lap.) 0.6 (0.4–0.9) 0.004 0.6 (0.5–0.9) 0.012
Pathological stage: <0.001 <0.001
– pTa/Tis 1, Reference – 1, Reference –
– pT1 1.5 (0.9–2.4) 0.145 1.2 (0.7–1.9) 0.570
– pT2 4.5 (2.9–7.1) <0.001 3.2 (2.0–5.1) <0.001
– pT3 10.1 (6.7–15.2) <0.001 5.9 (3.8–9.2) <0.001
– pT4 43.3 (27.4–68.4) <0.001 17.4 (10.3–29.4) <0.001
Grade 4.0 (3.0–5.2) <0.001 1.8 (1.3–2.4) <0.001
Lymphovascular invasion 3.9 (3.3–4.7) <0.001 1.6 (1.3–2.0) 0.001
Tumour architecture 4.0 (3.3–4.8) <0.001 1.3 (1.02–1.6) 0.029
Tumour necrosis 2.4 (1.9–2.9) <0.001 0.9 (0.7–1.1) 0.380
Concomitant CIS 1.5 (1.2–1.8) <0.001 1.0 (0.8–1.3) 0.766
LN stage <0.001 <0.001
– N0 1, Reference – 1, Reference –
– Nx 1.1 (0.8–1.4) 0.680 1.4 (1.1–1.9) 0.008
– N+ 4.9 (3.6–6.6) <0.001 2.1 (1.5–2.9) <0.001
Lap, laparoscopic.
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